Time is precious and so is your patient’s tumor sample. Make the most of both with the Oncotype MAP Pan-Cancer Tissue test.

Results in 3-5 business days*† from samples as small as 3mm2 of tissue‡, about the size of a grain of rice.
Current NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) “strongly advises broader molecular profiling with the goal of identifying rarer driver mutations for which effective drugs may already be available, or to appropriately counsel patients regarding the availability of clinical trials. Broad molecular profiling is a key component of the improved care of patients with NSCLC.”1
Explore the benefits of the Oncotype MAP Pan-Cancer Tissue Test

Why use a large panel? Benefits of comprehensive genomic testing

Testing a single gene at a time or utilizing a small biomarker panel can exhaust available tissue before you find the answer you need. A recent study found >60% of patients with NSCLC have an actionable mutation when a multigene testing panel is used compared to 25% (or less) when single gene testing is used.2

The Oncotype MAP Pan-Cancer Tissue test delivers comprehensive, personalized guidance and clinical trial-driven treatment recommendations in advanced cancer patients for fast results using a small amount of tissue. Worried that your sample size is too small? The Oncotype MAP test will provide quantity not sufficient (QNS) results in as few as 2 business days*† so you can make quick decisions for your patient.

Stay current with biomarker based therapeutic options

The continuous evolution in the precision oncology landscape for NSCLC has meant frequent updates to recommendations for biomarker testing and changes to the NCCN Guidelines®. The Oncotype MAP Pan-Cancer Tissue test identifies genomic alterations with both NGS and IHC signatures to help stay current with therapeutic options best suited to your patients per the NCCN’s latest recommendations in biomarker testing in record time.

Request Info or Book a Meeting

icon fast

FAST


Actionable results reported in 3-5 business days1
  • QNS results in as few as 2 business days
icon comprehensive

COMPREHENSIVE


Gold standard tissue testing includes all genes and biomarkers NCCN recommends for evaluation of NSCLC1 and more
icon actionable

ACTIONABLE


NCCN indicated therapies1
  • Continuously updated to include enrolling clinical trials
icon accurate

ACCURATE


99% sensitivity and specificity§ on small samples
  • Low QNS* rate
  • Compatible with small fine needle aspirates and tissues
  • FFPE samples as small as 3mm2, about the size of a grain of rice

Actionable indications for therapies and clinical trials

The Oncotype MAP Pan-Cancer Tissue test report provides clear, clinically actionable test results that are easy to interpret, helping you and your patient make confident, informed treatment decisions. The report offers potential therapeutic options and available clinical trials based on your patient’s key biomarkers, as well as detailed information on your patient’s specimen and genomic findings.

Download NSCLC Sample Report PDF

DOWNLOAD SAMPLE REPORT

Download NSCLC Report Interpretation Guide for Oncologists

DOWNLOAD REPORT GUIDE

Optimizing treatment for NSCLC

Relevant biomarkers for NSCLC analyzed by the Oncotype MAP test
Detected Mutations and Biomarkers Therapeutic Options1
Guideline and Relevant Markers
EGFR Tyrosine kinase inhibitors Afatinib and osimertinib, erlotinib, gefitinib, dacomitinib, ramucirumab, amivantamab
ALK Alectinib, brigatinib, crizotinib, ceritinib, lorlatinib, or entrectinib
ROS1 Crizotinib, ceritinib, entrectinib
BRAF BRAF inhibitors Dabrafenib, trametinib, vemurafenib
NTRK1-3 NTRK inhibitors Larotrectinib, entrectinib
MET MET inhibitors Crizotinib, capmatinib, or tepotinib
RET RET inhibitors Selpercatinib, pralsetinib, cabozantinib, vandetinib
PD-L1 Checkpoint inhibitors Pembrolizumab, cemiplimab
KRAS G12C KRAS inhibitor Sotorasib
Emerging Biomarkers
High-level MET Kinase inhibitors Crizotinib, capmatinib
ERBB2 Antibody-drug conjugates Ado-trastuzumab emtasine, fam-trastuzumab deruxtecan-nxki
MSI, MMR, TMB Checkpoint inhibitors Pembrolizumab
REFERENCES

  1. NCCN Guidelines Version 4.2021 - NSCLC https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf
  2. Kris MG, Johnson BE, Berry LD, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA. 2014;311:1998–1998

*Data on file.
† Turnaround time is based on qualified sample receipt.
‡ Morris S, Subramanian J, Gel E, Runger G, Thompson E, Mallery D, et al. Performance of next-generation sequencing on small tumor specimens and/or low tumor content samples using a commercially available platform. PLoS ONE. (2018); 13(4): e0196556. https://doi.org/10.1371/journal.pone.0196556
§ >99% sensitivity for SNVs and Indels. Detection down to ≥7.5% mutant allele frequency (MAF) with 99% specificity.

NCCN and NCCN Guidelines are trademarks of the National Comprehensive Cancer Network. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

Comparative turnaround time data on file.


*
*
*
*
*
*
I agree to be contacted by a representative of Exact Sciences about the Oncotype MAP test and accept the Terms & Conditions. For more information about our privacy practices, please read our Privacy Policy.*
 

Stay in Touch

Have questions? We're here to help.

 Contact Us
Copyright © 2004- Genomic Health, Inc. All Rights Reserved.
In the US and certain other jurisdictions, Genomic Health, Oncotype, Oncotype DX, Oncotype IQ, Oncotype MAP, Breast Recurrence Score, Recurrence Score, DCIS Score, Colon Recurrence Score, Genomic Prostate Score, GPS, AR-V7 Nucleus Detect, Pass It On: Until Every Woman Knows, and Making Cancer Care Smarter are trademarks of Genomic Health, Inc. Exact Sciences is a trademark of Exact Sciences Corporation.
Making cancer care smarter.™